Compare · NMRA vs VNDA

NMRA vs VNDA

Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Vanda Pharmaceuticals Inc. (VNDA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while VNDA focuses on Biotechnology: Pharmaceutical Preparations.
  • VNDA is the larger of the two at $230.4M, about 3.7x NMRA ($61.9M).
  • VNDA has been more active in the news (9 items in the past 4 weeks vs 5 for NMRA).
  • NMRA has more recent analyst coverage (23 ratings vs 6 for VNDA).
MetricNMRAVNDA
Company
Neumora Therapeutics Inc.
Vanda Pharmaceuticals Inc.
Price
-
-
Market cap
$61.9M
$230.4M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2023
2006
News (4w)
5
9
Recent ratings
23
6
VNDA

Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Latest NMRA

Latest VNDA